Title
Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV.

Permalink
https://escholarship.org/uc/item/2qb26283

Journal
mSystems, 5(5)

ISSN
2379-5077

Authors
Taylor, Bryn C
Weldon, Kelly C
Ellis, Ronald J
et al.

Publication Date
2020-10-13

DOI
10.1128/msystems.00528-20

Peer reviewed
Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV

Bryn C. Taylor,a Kelly C. Weldon,b,c Ronald J. Ellis,d,e Donald Franklin,f Daniel McDonald,g Gregory Humphrey,g MacKenzie Bryant,g Julia Toronczak,g Tara Schwartz,g Jennifer Iudicello,f Robert Heaton,f Igor Grant,f Sara Gianella,h Scott Letendre,l Austin Swafford,c Pieter C. Dorrestein,b,c,g Rob Knightc,g,k,l

aBiomedical Sciences Graduate Program, University of California San Diego, La Jolla, California, USA
bCollaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA
cCenter for Microbiome Innovation, University of California San Diego, La Jolla, California, USA
dDepartment of Neurosciences, HIV Neurobehavioral Research Center, University of California San Diego, La Jolla, California, USA
eDepartment of Psychiatry, HIV Neurobehavioral Research Center, University of California San Diego, La Jolla, California, USA
fDepartment of Psychiatry, School of Medicine, University of California San Diego, La Jolla, California, USA
gDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA
hDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA
iDepartment of Medicine, University of California San Diego, La Jolla, California, USA
jDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA
kDepartment of Computer Science and Engineering, University of California San Diego, La Jolla, California, USA
lDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA

Bryn C. Taylor and Kelly C. Weldon contributed equally to this work. Author order was determined by contribution.

ABSTRACT Alterations in the gut microbiome are associated with neurocognition and related disorders, including in the context of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. However, the connection between the gut microbiome and cognitive decline, gauged by increased dependence in instrumental activities of daily living (IADL), remains largely unexplored in the context of these diseases. Here we characterized the gut microbiome using 16S rRNA amplicon sequencing and untargeted metabolomics with liquid chromatography-mass spectrometry from 347 people with HIV, HIV and HCV, or neither, all of whom underwent a comprehensive neuropsychiatric assessment. We observed that IADL-dependent and -independent HIV-monoinfected (HIV-positive [HIV]+/HCV-negative [HCV−]) and coinfectected (HIV+/HCV+) individuals have distinct gut microbiomes. Moreover, we found that dependent individuals with HIV or HIV and HCV were enriched in Bacteroides. These results may have implications for the characterization of cognitive decline, as well as the development of potential prevention and treatment strategies for individuals infected with HIV and/or HCV. Of particular interest is the possibility that dietary interventions that are known to modify the microbiome could be used to shift the microbiome toward more favorable states for preserving independence.

IMPORTANCE The microbes in the gut and the chemicals they produce by metabolism have been linked to brain function. In earlier work, we showed that infection with two viruses, HIV and HCV, changed the gut microbes and metabolism in ways that were associated with a lifetime history of major depressive disorder. Here, we extend this analysis looking at a measurement of independence in daily living. We find that in individuals with HIV, whether or not they also have HCV, those who reported reduced independence were enriched in a genus of bacteria called Bacteroides. This result is interesting because Bacteroides is strongly associated with diets low in carbohydrates and high in animal protein, suggesting that diet changes may

Citation Taylor BC, Weldon KC, Ellis RJ, Franklin D, McDonald D, Humphrey G, Bryant M, Toronczak J, Schwartz T, Ludicello J, Heaton R, Grant I, Gianella S, Letendre S, Swafford A, Dorrestein PC, Knight R. 2020. Reduced independence in daily living is associated with the gut microbiome in people with HIV and HCV. mSystems 5:e00528-20. https://doi.org/10.1128/mSystems.00528-20.

Editor Casey S. Greene, University of Pennsylvania
Copyright © 2020 Taylor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Rob Knight, robknight@ucsd.edu.
Received 10 June 2020
Accepted 24 September 2020
Published 13 October 2020

msystems.asm.org

1
help preserve independent living in people living long-term with HIV (although clinical intervention trials would be needed in order to confirm this).

**KEYWORDS** IADL, gut microbiome, gut-brain axis, human immunodeficiency virus, hepatitis C virus

Aging is associated with cognitive decline and increased risk of dementia. Antiretroviral therapy (ART) extends the life span of HIV-positive (HIV+) individuals, but even adequately treated HIV increases risk for these conditions. Early signs of cognitive decline include impaired instrumental activities of daily living (IADL) and increased aging in HIV+ individuals (1, 2). Increased risk for impaired IADLs is greatest with lower CD4 counts or AIDS onset. Impaired ADL and IADLs are also associated with increased mortality (1, 3). Hepatitis C virus (HCV)-induced liver injury, a leading cause of mortality in HIV+ individuals, increases risk for impaired IADLs (4). More than 2,000,000 individuals worldwide are coinfected with HIV and HCV, and coinfection is particularly common in developed Western countries (5). Coinfected (HIV+/HCV+) individuals use more drugs, a known risk factor for acquiring HCV and substance-induced major depression. Coinfected individuals have exhibited impaired executive functioning, independent of liver disease severity (6). The gut microbiome is altered in individuals with HIV (7) and HCV (8), and we recently linked HIV- and HCV-associated changes in the gut microbiome and metabolome with major depressive disorder (9). Extending this work, we tested whether the gut microbiome and metabolome in HIV-HCV coinfection are also linked to changes in IADL.

We used a previously characterized group (9) of 398 participants with or without HIV or HCV infection from the University of California (UC) San Diego HIV Neurobehavioral Research Program, who underwent standardized evaluation of neuropsychiatric diagnoses using *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition (DSM-IV) (10) criteria (see “Methods” below) and provided fecal samples. A total of 347 samples from unique participants remained after applying filtering and exclusion criteria (see “Methods” below) and retaining only participants who reported their IADL status. Participants were grouped according to HIV and HCV infection status for analyses to assess the correlation of their daily living ability (IADL subgroups of “dependent” or “independent”; see “Methods” below; Table 1).

Dependent and independent individuals within each infection group are compared in Table 1. Gender and sexual practices in HIV patients may independently lead to differences in the gut microbiome (11), so we conducted a secondary analysis limited to men who have sex with men (MSM) (Table 2). Across all infection groups in the full cohort, we ran linear regressions for continuous variables and logistic regressions for categorical variables to look at the effects of IADL status on variables of interest. IADL dependence was significantly associated with greater neurocognitive impairment (higher continuous global deficit score [GDS], \( P = 0.03 \), and global impairment rate, \( P = 0.0043 \), unemployment (\( P < 0.0001 \)), more clinician-rated disability (lower Karnofsky rating, \( P < 0.0001 \)), more currently depressed mood (Beck Depression Inventory-II [BDI-II] score, \( P < 0.0001 \)), and higher rates of DSM-IV diagnoses of lifetime (\( P = 0.038 \) and current (\( P = 0.023 \)) major depressive disorder (MDD), and methamphetamine use disorder (DSM-IV diagnoses, \( P = 0.0005 \)). However, IADL dependence was not significantly related to demographics (age, education, sex, race/ethnicity, and MSM status) or estimated premorbid verbal intelligence quotient (IQ) (based upon Wide Range Achievement Test-IV reading level). The pattern of these findings strongly supports that the self-reports of increased IADL dependence in these groups represent acquired central nervous system compromise, likely due to multiple causes (HIV/HCV infections, prior methamphetamine use disorders, and affective illness).

Because neurobehavioral issues may result from altered gut microbiome composition and/or function, we tested for changes in overall gut microbiome diversity, assessed by 16S rRNA amplicon sequencing. In a subset of samples, the metabolome profile was assessed using untargeted liquid chromatography followed by tandem
mass spectrometry. In the gut metabolome, no beta diversity (i.e., between-subject, Bray-Curtis) differences were seen between IADL states in any of the infection groups (see Table S2 in the supplemental material). The gut metabolome was analyzed using a partial least-squares discriminant analysis to identify potential features of interest. Further inspection of individual features indicated no significant differences between IADL status in any infection groups for any class of compounds. We also did not observe community-wide microbiome differences between IADL states within the uninfected full cohort and MSM subgroup, as neither beta diversity (unweighted UniFrac; full cohort, permutational analysis of variance [PERMANOVA] pseudo-F-statistic [pseudo-F] = 1.074, Benjamini-Hochberg-corrected [BH] P = 0.30; MSM subgroup, PERMANOVA

---

**TABLE 1** Demographic information of the full cohort studied for the relationship between HIV, HCV, IADL, and the gut microbiome

| Characteristic | Value for the following subgroup: |
|---------------|----------------------------------|
|               | Uninfected (HIV−/HCV−) | HIV-monoinfected (HIV+/HCV−) | Coinfected (HIV+/HCV+) |
| n             | 10 | 91 | 73 | 127 | 54.7 (11.1) | 50.0 (12.2) | 0.008 | 54.7 (10.6) | 53.0 (8.1) | 22 | 24 |
| Gender        | % male | 60 | 60 | 86 | 87 | 77 | 92 |
| % female      | 40 | 40 | 14 | 13 | 23 | 8 |
| Ethnicity     | % African American | 20 | 19 | 18 | 19 | 36 | 33 |
| % Caucasian   | 40 | 59 | 62 | 56 | 32 | 46 |
| % Hispanic    | 20 | 20 | 16 | 20 | 32 | 21 |
| % other       | 20 | 2 | 4 | 5 | 0 | 0 |
| Estimated verbal IQ | 99.2 (19.5) | 105.6 (15.3) | 102.2 (12.9) | 101.8 (12.6) | 100.5 (16.0) | 98.2 (11.8) |
| Sexual orientation (%) | | | | | | |
| Bisexual      | 0 | 8 | 6 | 10 | 23 | 13 |
| Heterosexual  | 70 | 70 | 23 | 18 | 27 | 26 |
| Homosexual    | 30 | 22 | 70 | 71 | 50 | 61 |
| Other/not asked | 1 | 1 |
| % AIDS        | | | | | | | 77 | 67 |
| Estimated duration of infection (yr) | 19.9 (9.3) | 16.4 (10.0) | 0.0183 | 21.6 (8.6) | 22.0 (6.7) |
| Nadir CD4+    | 135 (13–246) | 200 (43–352) | 0.0281 | 169 (17–254) | 112 (7–284) |
| Current CD4+  | 617 (452–902) | 638 (482–829) | 0.480 (295–796) | 588 (456–848) |
| % undetectable plasma on ART | 87 | 88 | 72 | 94 |
| % undetectable CSF on ART | 96 | 89 | 82 | 100 |
| ART status    | % HAART | 96 | 97 | 86 | 88 |
| % off ARVS    | 4.0 | 1.5 | 14.0 | 8.0 |
| % ARV naive   | 0.0 | 1.5 | 0.0 | 4.0 |
| % employed    | 22 | 46 | 16 | 43 | 0.0002 | 0.35 | 0.004 |
| Karnofsky disability rating | 89 (9.9) | 98.0 (6.8) | 84.3 (14.3) | 95.4 (8.0) | <0.0001 | 73.5 (16.0) | 92 (12.4) | 0.0002 |
| BDI-IIa       | 13 (10.6) | 4.9 (6.5) | 0.0013 | 16.2 (12.2) | 7.9 (8.4) | <0.0001 | 16.4 (11.5) | 6.7 (7.2) | 0.002 |
| GDS           | 0.77 (0.50) | 0.54 (0.53) | 0.64 (0.49) | 0.56 (0.54) | 0.86 (0.68) | 0.58 (0.59) |
| GDS impairment (%) | 75 | 39 | 56 | 45 | 68 | 43 |
| MDD (%)       | Lifetime | 40 | 32 | 58 | 50 | 86 | 58 |
|               | Current | 10 | 2 | 9 | 4 | 10 | 0 |
| Any substance Dx (%) | Lifetime | 70 | 51 | 74 | 73 | 91 | 83 |
|               | Current | 10 | 10 | 7 | 7 | 15 | 5 |

Note:

- Student’s t tests were used for all normally distributed continuous variables (age, education, estimated verbal IQ, estimated duration of HIV infection, and GDS).
- Wilcoxon tests were used for nadir CD4, current CD4, BDI-II, and Karnofsky disability rating. Chi-square tests were used for all nominal variables (percent Caucasian, percent AIDS, percent undetectable plasma on ART, percent undetectable CSF on ART, percent bisexual and/or homosexual, ART status, percent employed, lifetime MDD, lifetime methamphetamine Dx, lifetime sedative Dx, and lifetime any substance Dx). The P value column for each infection group indicates whether the IADL groups within that infection type show a significant difference (alpha = 0.05).
- ART, antiretroviral therapy; CSF, cerebrospinal fluid; HAART, highly active antiretroviral therapy; ARV, antiretroviral; BDI-II, Beck Depression Inventory-II; GDS, global deficit score; MDD, major depressive disorder; Dx, substance use disorder.
- dep., dependent; indep., independent.
- Mean (standard deviation) shown for these characteristics.
- Median (interquartile range [IQR]) shown for these characteristics.
TABLE 2 Demographic information of the MSM subgroups studied for the relationship between HIV, HCV, IADL, and the gut microbiome\(^a\)

| Characteristic                          | Value for the following subgroup\(^b\): | HIV-monoinfected (HIV+/HCV−) | Coinfected (HIV+/HCV+) |
|----------------------------------------|-----------------------------------------|-----------------------------|------------------------|
|                                        | Uninfected (HIV−/HCV−)                  |                              |                        |
|                                        | IADL dep. | IADL indep. | P value | IADL dep. | IADL indep. | P value | IADL dep. | IADL indep. | P value |
| N                                      |           |             |         |           |             |         |           |             |         |
| Age (yr)\(^d\)                         | 43 (31.3) | 54.1 (15.0) | 0.92    | 3.2 (11.7) | 50.2 (13.2) | 0.55    | 3.6 (11.6) | 52 (6.6)     |        |
| Education (yr)\(^d\)                   | 15 (2.6)  | 15.0 (2.4)  | 0.92    | 14.4 (2.5) | 14.5 (2.4)  | 0.55    | 14.0 (2.8) | 13.2 (2.3)   |        |
| Ethnicity                              |                                       |                             |                        |
| % African American                     | 0        | 0.14        | 0.92    | 0.12       | 0.12       | 0.55    | 0.25       | 0.24        |
| % Caucasian                            | 34       | 68          | 0.92    | 65         | 64         | 0.55    | 38         | 53          |
| % Hispanic                             | 33       | 14          | 0.92    | 19         | 20         | 0.55    | 37         | 23          |
| % other                                | 33       | 4           | 0.92    | 4          | 10         | 0.55    | 0          | 0           |
| Estimated verbal IQ\(^d\)              | 111.3 (14.6) | 110.6 (18.1) | 103.9 (11.8) | 102.5 (11.4) | 103.8 (17.1) | 100.7 (10.0) |
| Sexual orientation (%)                 |                                       |                             |                        |
| Bisexual                               | 0        | 23          | 0.92    | 8          | 11         | 0.55    | 31         | 18          |
| Homosexual                             | 100      | 77          | 0.92    | 92         | 89         | 0.55    | 69         | 82          |
| % AIDS                                 |           |             |         |           |             |         |           |             |         |
| Estimated duration of infection (yr)\(^d\) | 20.6 (9.8) | 16.5 (10.5) | 0.92    | 21.9 (9.5) | 23.0 (6.9) | 0.55    | 178 (22–458) | 114 (9–298) |
| Nadir CD4\(^e\)                        | 135 [20–250] | 209 [79–400] | 0.92    | 187 (22–458) | 114 [9–298] | 0.55    | 405 [268–725] | 529 [455–828] |
| Current CD4\(^e\)                      | 612 [448–910] | 643 [473–820] | 0.92    | 77         | 100        | 0.55    | 77         | 100         |
| % undetectable plasma on ART            | 84       | 87          | 0.92    | 84         | 87         | 0.55    | 88         | 100         |
| % undetectable CSF on ART              | 100      | 100         | 0.92    | 100        | 100        | 0.55    | 100        | 100         |
| ART status                             |                                       |                             |                        |
| % HAART                                | 94       | 96          | 0.92    | 88         | 88         | 0.55    | 88         | 88          |
| % off ARVS                             | 6.0      | 2.0         | 0.92    | 12.0       | 6.0        | 0.55    | 12.0       | 6.0         |
| % ARV naive                            | 0.0      | 2.0         | 0.92    | 0.0        | 6.0        | 0.55    | 0.0        | 6.0         |
| % employed                             | 33       | 38          | 0.92    | 13         | 43         | 0.0003  | 40         | 44          |
| Karnofsky disability rating            | 90 (10)  | 96.2 (11.2) | 0.92    | 83.6 (14.6) | 95.4 (8.0) | 0.0003  | 74.7 (17.7) | 92.3 (11.7) |
| BDII\(^c\)                             | 12 (7.5) | 6 (6.8)     | 0.92    | 16.5 (12.6) | 8.3 (8.9)  | 0.0003  | 15.1 (12.0) | 5.2 (4.8)   |
| GDS                                    | 0.57 (0.45) | 0.56 (0.51) | 0.92    | 0.61 (0.43) | 0.57 (0.56) | 0.0003  | 0.95 (0.73) | 0.57 (0.64) |
| GDS impairment (%)                     | 67       | 38          | 0.92    | 53         | 47         | 0.0003  | 71         | 38          |
| MDD                                    |                                       |                             |                        |
| Lifetime (%)                           | 33       | 32          | 0.92    | 54         | 51         | 0.0003  | 81         | 47          |
| Current                                | 0        | 0           | 0.92    | 8          | 4          | 0.0003  | 13         | 0           |
| Any substance Dx (%)                   |                                       |                             |                        |
| Lifetime                               | 67       | 77          | 0.92    | 77         | 75         | 0.0003  | 88         | 88          |
| Current                                | 0        | 14          | 0.92    | 4          | 7          | 0.0003  | 13         | 0           |

\(^a\)Student’s t tests were used for all normally distributed continuous variables (age, education, estimated verbal IQ, estimated duration of HIV infection, and GDS).

\(^b\)Wilcoxon tests were used for nadir CD4, current CD4, BDII, and Karnofsky disability rating. Chi-square tests were used for all nominal variables (percent Caucasian, percent AIDS, percent undetectable plasma on ART, percent undetectable CSF on ART, percent bisexual and/or homosexual, ART status, percent employed, lifetime MDD, lifetime methamphetamine Dxs, lifetime sedative Dxs, and lifetime any substance Dxs). The \(P\) value column in each infection group, \(P\) value, indicates whether the IADL groups within that infection type show a significant difference (alpha = 0.05).

\(^c\)ART, antiretroviral therapy; CSF, cerebrospinal fluid; HAART, highly active antiretroviral therapy; ARV, antiretroviral; BDII, Beck Depression Inventory-II; GDS, global deficit score; MDD, major depressive disorder; Dx, substance use disorder.

\(^d\)dep., dependent; indep., independent.

\(^e\)Mean (standard deviation) shown for these characteristics.

\(^f\)Median (interquartile range [IQR]) shown for these characteristics.

\(\text{pseudo-F} = 0.92, \text{BH } P = 0.55\) nor alpha diversity (i.e., within subject; Faith’s phylogenetic diversity [PD]; full cohort, Kruskal-Wallis [K-W] \(H = 0.058, \text{BH } P = 0.81\); MSM subgroup, K-W \(H = 0.028, \text{BH } P = 0.87\) differed between dependent (full cohort, \(n = 7\); MSM subgroup, \(n = 22\)) and independent (full cohort, \(n = 94\); MSM subgroup, \(n = 3\)) individuals. However, there were few dependent individuals, so the chance of type II error is high.

In contrast, in each of the infection groups and MSM subgroups, we observed significant community-wide microbiome differences between dependent and independent individuals. In the HIV-monoinfected (HIV+/HCV-negative [HCV−]) groups, there was a difference in beta diversity (unweighted UniFrac; full cohort, PERMANOVA pseudo-F = 1.72, BH \(P = 0.02\); MSM subgroup, pseudo-F = 1.56, BH \(P = 0.034\)), but not in alpha diversity, between the IADL groups (Faith’s PD; full data set, K-W \(H = 2.79, BH P = 0.095\); MSM data set, K-W \(H = 0.93, P = 0.34\)). In the coinfected groups, beta
diversity differed between independent and dependent individuals (unweighted UniFrac; full data set, PERMANOVA pseudo-F/H11005/1.95, BH P/H11005/0.008; MSM data set, PERMANOVA pseudo-F-statistic/H11005/2.076, BH P/H11005/0.003), and coinfected independent individuals had higher alpha diversity than dependent individuals (Faith’s PD; full data set, K-W H/H11005/7.79, BH P/H11005/0.0053; MSM data set, K-W H/H11005/8.523, BH P/H11005/0.0035).

Conserved community-wide microbiome differences according to IADL status within both the HIV-monoinfected and coinfected (HIV+/HCV−) full cohorts and MSM subgroups prompted us to identify taxa enriched in dependent individuals. We computed the log ratio of the highest 30% (“Set 1” in Table S1) and lowest 30% (“Set 2” in Table S1) of the ranked suboperational taxonomic units (sOTUs) associated with IADL status in the HIV-monoinfected MSM subgroup using Songbird (12), visualized with Qurro (13) (see “Methods” below). We performed the same analysis using the coinfected MSM subgroup and computed the log ratio of the highest 30% (“Set 3” in Table S1) and lowest 30% (“Set 4” in Table S1) of ranked sOTUs associated with IADL status in the coinfected MSM subgroup. Both cases revealed significant differences in log ratios of features distinguishing independent from dependent individuals (HIV-monoinfected individuals, Fig. 1a and b, t test P/H11005/3.35e−10, t/H11005/−6.74; coinfected individuals, Fig. 1c and d, t test P/H11005/0.00062, t/H11005/H11002/3.82). The HIV-monoinfected and coinfected feature sets had shared sOTUs: set 1 and set 3 had 8 sOTUs in common, and set 2 and set 4 had 17 sOTUs in common. The same feature sets were also used successfully to distinguish IADL-dependent from -independent individuals in the full HIV-monoinfected and coinfected groups (HIV-monoinfected group, t test P/H11005/8.0e−06, t/H11005/−4.85; coinfected group, t test P/H11005/0.0032, t/H11005/−3.25). Although identification of particular microbes associated with these disease states is limited, of interest is Bacteroides which has been previously associated with mild cognitive impairment and lower global cognitive function (14), present in 8.1% (15/186 total features) in set 1 but only 3.2% (6/186) in
set 2 and 12.5% (6/48) in set 3 but 0% (0/48) in set 4, suggesting that *Bacteroides* is enriched in IADL-dependent people in both the HIV-monoinfected and coinfected infection groups. The proportion of *Bacteroides* sOTUs in the unselected feature space was 2.4% (6/251) and 3.0% (2/66) for HIV-monoinfected and coinfected MSM subgroups, respectively. Since IADL may be plausibly linked to sexual practice, and the ratio of *Bacteroides* to *Prevotella* has been reported to be associated with sexual practice, changes in *Bacteroides* should be interpreted with caution. Notably, because *Bacteroides* can be decreased in the human gut by increasing carbohydrate intake and/or reducing animal protein (15), dietary changes may prevent or treat microbiome-based cognitive decline in these populations.

**Methods.** (i) Participant recruitment, sample processing, and sample selection. This was a cross-sectional prospective observational cohort study of persons with or without HIV infection recruited from community sources, who agreed to undergo comprehensive neuromedical and neurobehavorial evaluations for NIH-funded studies at the HIV Neurobehavioral Research Program (HNR) (https://hnpr.hivresearch.ucsd.edu/) including the HIV Neurobehavioral Research Center (HNRC) study (study details, HNR [16]) at the University of California San Diego (UCSD). Those who also agreed to submit stool samples for microbiome studies were included in the current analyses. A subset of participants also had positive serology for hepatitis C virus. The UCSD’s Human Research Protections Program (irb.ucsd.edu) approved all study procedures, and all participants provided written informed consent (UCSD institutional review board [IRB] protocol number 172092).

Exclusions were diagnoses of active substance use disorders and presence of an active, major psychiatric condition with current psychotic features or neurological conditions such as schizophrenia or epilepsy. If multiple stool samples were collected from participants, only the first time point was analyzed by 16S rRNA sequencing. A single time point per subject was additionally analyzed by high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS). HIV and HCV infection was confirmed by a point-of-care vertical flow test (MedMira, Halifax, Nova Scotia). Participants were designated (i) “HIV monoinfected” if they tested positive for HIV but not HCV, (ii) “coinfected” if they tested positive for both HIV and HCV, or (iii) “uninfected” if they tested positive for neither HIV or HCV.

(ii) Psychiatric assessment. Psychiatric and substance use diagnoses were obtained using the Composite International Diagnostic Interview (CIDI) (www.hcp.med.harvard.edu/wmhidcidi/), a fully structured, computer-based interview, to determine DSM-IV diagnoses for current and lifetime mood and substance use disorders. DSM-IV diagnosis of lifetime and current major depressive disorder was evaluated using CIDI. Current self-reported depressed mood was assessed using the Beck Depression Inventory-II. The BDI-II consists of 21 items that assess the severity of depression symptoms over the 2 weeks prior to assessment. The BDI-II total score ranges from 0 to 63 with higher scores denoting more severe depression symptoms. For analyses, we used the published cutoff of at least mild severity to define current self-reported depression. Parameters of lifetime substance use were estimated using a semistructured timeline follow-back interview (TLFBI) as previously described (17). The TLFBI uses a calendar method to evaluate daily patterns and frequency of substance use over a specified time period. It has high retest reliability, convergent and discriminant validity with other measures, agreement with collateral informants’ reports of patients’ substance use, and agreement with results from patients’ urine assays.

(iii) Assessments of measured activities of daily living. Dependence in instrumental activities of daily living (IADLs) was assessed with a modified version of the Lawton and Brody Scale that asks participants to rate their current and best lifetime levels of independence for 13 major IADLs such as shopping, financial management, transportation, and medication management. An employment questionnaire asked about the following: job loss; decreases in work productivity, accuracy, and quality;
increased effort required to do one’s usual job; and increased fatigue with the usual workload.

(iv) Neuromedical and laboratory assessment. All participants underwent a comprehensive neuromedical assessment, including a medical history that collected antiretroviral therapy (ART) and other medications, data to determine Centers for Disease Control and Prevention (CDC) staging, and specimen collection (blood, stool). Routine clinical chemistry panels, complete blood counts, rapid plasma reagin, and CD4+ T cells (flow cytometry) were performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified medical center laboratory. HIV RNA was measured in plasma using reverse transcriptase PCR (Amplicor, Roche Diagnostics, Indianapolis, IN) with a lower limit of quantitation of 40 copies/ml.

(v) 16S rRNA gene sequencing. DNA extraction and 16S rRNA amplicon sequencing were done using Earth Microbiome Project (EMP) standard protocols (http://www.earthmicrobiome.org/protocols-and-standards/16s). DNA was extracted with the Qia-gen MagAttract PowerSoil DNA kit as previously described (18). Amplicon PCR was performed on the V4 region of the 16S rRNA gene using the primer pair 515f to 806r with Golay error-correcting barcodes on the reverse primer. Amplicons were barcoded and pooled in equal concentrations for sequencing. The amplicon pool was purified with the MO BIO UltraClean PCR cleanup kit and sequenced on the Illumina MiSeq sequencing platform. Sequence data were demultiplexed and minimally quality filtered using the Qiita defaults.

(vi) 16S marker gene data analysis. QIIME 2 v2020.2 (19) was used to rarefy to 2,500 sequences/sample and to generate pairwise unweighted UniFrac distances. Between-group differences based on these distances were tested using PERMANOVA and permuted t tests in QIIME 2. Alpha diversity (Faith’s PD) was compared with a Kruskal-Wallis test.

Songbird v1.0.1 (12) in QIIME 2 version 2020.2 was used to identify feature ranks (parameters: –p-epochs 10000 –batch-size 5 –learning-rate 1e-4 –min-sample-count 1000 –min-feature-count 0 –num-random-test-examples 10% of samples), and Qurro v0.4.0 (13) was used to compute log ratios of these ranked features. Evaluation of the Songbird models against a baseline model obtained a pseudo-Q2 value of >0, suggesting that the models were not overfit, except for the coinfected full group model which had a pseudo-Q2 of −0.048 and suggests possible overfitting related to the subtlety of the differences between IADL states in coinfected individuals when not accounting for sexual preferences. t tests were calculated to assess the significance (alpha = 0.05) of the log ratios.

(vii) LC-MS/MS data acquisition. Data acquisition protocols follow the Center for Microbiome Seed Grant Metabolomics standards, as performed in the study of Taylor et al. (9). Human fecal samples were transferred to clean 2-ml sample tubes (Qiagen catalog no. 990381), and the weights were recorded. The samples were then extracted in a 1:1 solution of methanol to water spiked with an internal standard of 1 μM sulfamethazine, using a 1:10 sample weight (milligram) to solvent volume (microliter) ratio. Using a Tissuelyser II (Qiagen), the samples were homogenized for 5 min at 25 Hz. This was followed by a 15-min centrifugation at 14,000 rpm. From the supernatant, 400 μl was transferred to a prelabeled 96-well DeepWell plate, and the plates were concentrated using a CentriVap benchtop vacuum concentrator (Labconco) for approximately 4 h. The dry plates were placed into the −80°C freezer until time for analysis.

The plates were resuspended in 150 μl of a 1:1 solution of methanol to water with a 1 μM sulfadimethoxine internal standard solution. For metabolomics analysis, an ultrahigh performance liquid chromatography system (Thermo Dionex Ultimate 3000 UHPLC) coupled to an ultrahigh resolution quadrupole time of flight (qToF) mass spectrometer (Bruker Daltonics MaXis HD). For chromatographic separation, a Phenomenex Kinetex column (C18, 1.7 μm, 2.1 mm by 50 mm) was used. The mobile phase consisted of solvent A (100% LC-MS grade water with 0.1% formic acid) and solvent B (100% acetonitrile with 0.1% formic acid). Each sample was injected at a volume of 5 μl into a flow rate of 0.5 ml for the entire analysis. The 12-min chromatographic gradient
began at 5% solvent B for the first minute, an increase to 100% solvent B from minute 1 to minute 11, a hold at 100% solvent B until minute 11.5, and back down to 5% solvent B reached at minute 11.5. All data were collected using electrospray ionization in positive mode. Positive mode was selected in order to allow for spectral matches to be found using the Global Natural Products Social Molecular Networking (GNPS) spectral libraries, a majority of which were collected in positive ionization mode. Data-dependent acquisition was set to a scan range of 100 to 2,000 m/z.

(viii) LC-MS/MS data analysis. The raw data in Bruker (.d) format were lock mass corrected using hexakis ((1H, 1H, 2H-difluoroethoxy)phosphazene (Synquest Laboratories, Alachua, FL) and were exported as .mzXML files using the Bruker Data Analysis software. Both the raw .d and the .mzXML files were uploaded to the UC San Diego mass spectrometry data repository MassIVE (https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp). Feature detection was completed using MZmine version 2.37 software (20). The resulting feature tables were exported as both a quantification file (.csv) and a spectral information file (.mgf) for analysis using the Global Natural Products Social Molecular Networking platform (21).

The quantification table and spectral information were analyzed using the GNPS feature-based molecular networking workflow. Parameters can be viewed via the job results page (https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=350392e8e24c41f2b84fde04f9183fc4). Also available at this job result page is access to the molecular networks and library annotations for the entire data set. This data set consisted of 1,911 unique MS/MS spectra, of which 313 had a spectral match to the GNPS reference libraries (https://gnps.ucsd.edu/ProteoSAFe/libraries.jsp), including matches to drug metabolites, bile acids, food-related compounds, and dipeptide molecules. For the statistical analyses, the MZmine-produced feature abundance table containing peak areas was input into the web-based MetaboAnalyst software. The data were normalized following the metabolomics data analysis protocols outlined in the previous metabolomics project (22), a normalization by quantile normalization and an auto scale. The normalized data were used to calculate a squareform matrix based on the Bray-Curtis distance metric which was input into a .qza format for use in QIIME 2. All PERMANOVAs were run using the QIIME 2 beta group significance command (19). Individual feature level comparisons were completed using a Dunn’s test.

(ix) Data availability. The data generated in this study are available publicly in Qiita under the study identifier (ID) 11135 (https://qiita.ucsd.edu/study/description/11135), and sequence data associated with this study have been deposited at EBI/ENA under accession number ERP122366. The GNPS feature-based molecular networking job is available at https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=350392e8e24c41f2b84fde04f9183fc4. The raw experimental data are available at MassIVE (https://massive.ucsd.edu), data set MSV000083664.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

TABLE S1, CSV file, 0.1 MB.
TABLE S2, CSV file, 0.01 MB.

ACKNOWLEDGMENTS
This work was supported by U19AG063744 and a Seed Grant from the Center for Microbiome Innovation. We thank Lindsay DeRight-Goldasich, A. Cole Heale, and Karenina Sanders for sample processing, Gail Ackermann for assistance with metadata curation, and Jeff DeReus for data handling and processing.

The HIV Neurobehavioral Research Center (HNRC) is supported by Center award P30MH062512 from NIMH. The San Diego HIV Neurobehavioral Research Center (HNRC) group is affiliated with the University of California San Diego, the Naval Hospital in San Diego, and the Veterans Affairs San Diego Healthcare System, and includes the following: Director, Robert K. Heaton; Co-Director, Igor Grant; Associate Directors, J. Hampton Atkinson, Ronald J. Ellis, and Scott Letendre; Center Manager, Jennifer Iudicello; Donald
Franklin, Jr.; Melanie Sherman; NeuroAssessment Core; Ronald J. Ellis (principal investigator [PI]); Scott Letendre, Thomas D. Marcotte, Christine Fennema-Notestine, Debra Rosario, and Matthew Dawson; NeuroBiology Core, Cristian Achim (PI), Ana Sanchez and Adam Fields; NeuroGerm Core, Sara Gianella Weibel (PI), David M. Smith, Rob Knight, and Scott Peterson; Developmental Core, Scott Letendre (PI) and J. Allen McCutchan; Participant Accrual and Retention Unit, J. Hampton Atkinson (PI), Susan Little, and Jennifer Marquie-Beck; Data Management and Information Systems Unit, Lucila Ohno-Machado (PI) and Clint Cushman; Statistics Unit Ian Abramson (PI), Florin Vaida (co-PI), Anya Umlauf, and Bin Tang.

REFERENCES

1. Erlandson KM, Schrack JA, Jankowski CM, Brown TT, Campbell TB. 2014. Functional impairment, disability, and frailty in adults aging with HIV-infection. Curr HIV/AIDS Rep 11:279–290. https://doi.org/10.1007/s11904-014-0215-y.

2. Heaton RK, Marcotte TD, Rivera Mindt M, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I, Atkinson JH, Wallace MR, Ellis RJ, Letendre S, Schrier R, Chernier M, Rippeth J, Woods S, Semigan T, Hesselink J, Masliah E, Masry DR, Frybarger M, Abramson I, Deutsch R, Wolfson T. 2004. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10:317–331. https://https://doi.org/10.1017/S1355617704012103.

3. Stanton DL, Wu AW, Moore RD, Rucker SC, Piazza MP, Abrams JE, Chaisson RE. 1994. Functional status of persons with HIV infection in an ambulatory setting. J Acquir Immune Defic Syndr 7:1050–1056.

4. Samoylova ML, Kovensky KE, Haftek M, Kuo S, Roberts JP, Lai JC. 2016. Prevalence and burden of HCV coinfection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 16:797–808. https://https://doi.org/10.1016/S1473-3099(15)00485-5.

5. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. 2004. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 62:957–962. https://https://doi.org/10.1212/00059255-1997749766C.

6. Dillen SM, Frank DN, Wilson CC. 2016. The gut microbiome and HIV-1 pathogenesis: a two-way street. AIDS 30:2737–2751. https://https://doi.org/10.1097/QAD.0000000000001289.

7. Inoue T, Nakayama J, Moriya K, Kawarataki H, Momoda R, Ita K, Ito E, Nojiri S, Fujikawa K, Yoneda M, Yoshii H, Tanaka Y. 2018. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis 67:869–877. https://https://doi.org/10.1093/cid/ciy1205.

8. Taylor BC, Weldon KC, Ellis RJ, Franklin D, Groth T, Gentry EC, Tripathi A, Marotz C, Amir A, Humphrey G, Gaffney J, Gogul K, Knight R. 2017. DNA extraction for streamlined metagenomics of diverse environmental samples. Biotechniques 62:290–293. https://https://doi.org/10.2164/biotechniques.62.2.290.

9. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny J, Razavi H, Vickerman P. 2016. Prevalence and burden of HCV coinfection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 16:797–808. https://https://doi.org/10.1016/S1473-3099(15)00485-5.

10. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, 4th ed. American Psychiatric Publishing Inc, Washington, DC.

11. Armstrong AJ, Shaffer M, Nusbacher NM, Griesmer C, Fiorillo S, Schneider JM, Preston Neff C, Li SX, Fontenot AP, Campbell T, Palmer BE, Lozupone CA. 2018. An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men. Microbiome 6:198. https://https://doi.org/10.1186/s40168-018-0580-7.

12. Morton JT, Marotz C, Washburne A, Silverman J, Zaramela LS, Edlund A, Ziegler K, Knight R. 2019. Establishing microbial composition measurement standards with reference frames. Nat Commun 10:2719. https://https://doi.org/10.1038/s41467-019-10656-5.

13. Fedarko MW, Martino C, Morton JT, González A, Rahman G, Marotz CA, Minich JJ, Allen EE, Knight R. 2019. Visualizing ‘omic feature rankings and log-ratios using Quroo. bioRxiv https://https://https://doi.org/10.1101/2019.12.17.880447.

14. Saji N, Niida S, Muratori K, Hisada T, Tsudsuki T, Sugimoto T, Kimura A, Toba K, Sakurai T. 2019. Analysis of the relationship between the gut microbiome and dementia: a cross-sectional study conducted in Japan. Sci Rep 9:10088. https://https://doi.org/10.1038/s41598-018-38218-7.

15. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Blevins T, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, bushman FD, Lewis JD. 2011. Linking long-term dietary patterns with gut microbial enterotypes. Science 334:105–108. https://https://doi.org/10.1126/science.1208344.

16. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Rivera Mindt M, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McCarthy JC, Simpson DM, Abramson I, Gamanast A, Fennema-Notestine C, Cemigan TL, Wong J, Grant I, for the CHARTEGRoup. 2011. HlV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature. J Neurovirol 17:3–16. https://https://https://doi.org/10.1007/s11365-010-0006-1.

17. Sobell MB, Sobell LC. 2007. Substance use, health, and mental health. Clin Psychol Sci Pract 14:1–5. https://https://doi.org/10.1111/j.1468-2850.2007.00056.x.

18. Marotz C, Amir A, Humphrey G, Gaffney J, Gogul K, Knight R. 2017. DNA extraction for streamlined metagenomics of diverse environmental samples. Biotechniques 62:290–293. https://https://doi.org/10.2164/biotechniques.62.2.290.

19. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EL, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Birenboim A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodriguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM, Durall DM, Duvallet C, Edwardsford CF, Ernst M, Estaki M, Fouquier J, Gauglitz JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H, Hutterer C, Hurtley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Kang KB, Keefe CR, Keim P, Kelley ST, Knights D, Koester I, et al. 2019. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 37:852–857. https://https://doi.org/10.1038/s41587-018-0209-9.

20. Pluskal T, Castillo S, Villar-Broges A, Oresic M. 2010. M2dmine: 2 modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinform 11:395. https://https://doi.org/10.1186/1471-2105-11-395.

21. Wang M, Carver JJ, Phelan WV, Sanchez LM, Garg N, Peng Y, Nguyen DD, Watrous J, Kapono CA, Luzzatato-Knaan T, Porto C, Bouslimani A, Melnik AV, Meehan MJ, Liu WT, Crusemann M, Boudreau PD, Esquenazi S, Sandoval-Calderon M, Kersten RD, Pace LA, Quinna AR, Dran AR, Hsu CC, Flores DJ, Galvani RG, Kleigrewe K, Northen T, Dutton RJ, Parrot D, Carlon EE, Aigle B, Michelsen CF, Jelsbak L, Søhlenkamp C, Pvezner P, Edlund A, McLean J, Piel J, Murphy BT, Kersten RD, Skaflestad BE, Klitgaard A, et al. 2016. Sharing and community curation of mass spectrometry-based molecular profile data. Nat Biotechnol 34:828–838. https://https://doi.org/10.1038/nbt.3597.

22. Vaidya CA, Lejezerowicz F, Poirel M, Shaffer JP, Jiang L, Aksenenov A, Litvin N, Humphrey G, Martino C, Miller-Gonzalez S, Dorrestein PC, Veiga P, Song SJ, McDonald D, Derrien M, Knight R. 2020. Consumption of fermented foods is associated with systematic differences in the gut microbiome and metabolome. mSystems 5:e00919-19. https://https://doi.org/10.1128/mSystems.00919-19.